Launching the BIOSPIT initiative: Harmonizing sputum outcomes in multicenter trials

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 3, 2013, Pages 400-401

  Clarke, Graham W ^a,b   Diamant, Zuzana ^c   Greenaway, Steven D ^a   Rainer, Margaret ^a   Allen, Elizabeth ^a   Gispert, Juan ^a  

^a IQVIA   (United States)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Early drug development; Multicenter studies; Sputum biomarkers

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; HYPERTONIC SOLUTION;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; DISEASE EXACERBATION; EOSINOPHILIA; EXPERIMENTAL THERAPY; GOLD STANDARD; HUMAN; LETTER; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEOMICS; RESPIRATORY TRACT ALLERGY; SEVERE PERSISTENT ASTHMA; SPUTUM; SPUTUM ANALYSIS; STANDARDIZATION;

ASTHMA; CLINICAL PROTOCOLS; HUMANS; INFLAMMATION MEDIATORS; MULTICENTER STUDIES AS TOPIC; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM;

EID: 84875932744     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2012.12.007     Document Type: Letter

References (9)

1. Diamant Z., Tarasevych S., Clarke G.W. New and existing pharmacotherapeutic options for asthma and obstructive airways disease. Neth J Med 2011 Nov-Dec, 69(11):486-499.
2. Morrow Brown H. Treatment of chronic asthma with prednisolone: significance of eosinophils in the sputum. Lancet 1958, 2:1245-1247.
3. Pin I., Gibson P.G., Kolendowicz R., Girgis-Gabardo A., Denburg J.A., Hargreave F.E., et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992 Jan, 47(1):25-29.
4. Fahy J.V., Liu J., Wong H., Boushey H.A. Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. Am Rev Respir Dis 1993 May, 147(5):1126-1131.
5. Djukanović R., Sterk P.J., Fahy J.V., Hargreave F.E. Standardised methodology of sputum induction and processing. Eur Respir J 2002 Sep, 37(Suppl):1s-2s.
6. Spanevello A., Beghé B., Bianchi A., Migliori G.B., Ambrosetti M., Neri M., et al. Comparison of two methods of processing induced sputum: selected versus entire sputum. Am J Respir Crit Care Med 1998, 157(2):665-668.
7. Bakakos P., Schleich F., Alchanatis M.,R. Louis. Induced sputum in asthma: from bench to bedside. Curr Med Chem 2011, 18:1415-1422.
8. Leckie M.J., ten Brinke A., Khan J., Diamant Z., O'Connor B.J., Walls C.M., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000 Dec 23-30, 356(9248):2144-2148.
9. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009 Mar 5;360(10):985-93.